Výsledky vyhledávání

Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy

Autor: George Koumakis, Jacques Thiriaux, Jean-Paul Sculier, Thierry Berghmans, V. Giner, P. VanHoutte, Peggy Wackenier, P. Lothaire, Paul Mommen, Jean-Jacques Lafitte, Michel Richez, J.-L. Corhay, Anna Efremidis, J. Lecomte, Vincent Ninane

Publikováno v: Lung Cancer. 45:339-348

The 1997 International staging system (ISS) classification separated stage III non-small cell lung cancer (NSCLC) into stages IIIA and IIIB. In a previous study including unresectable NSCLC initially treated with chemotherapy, we analysed survival ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0da83b4788193883be8dd4719656143
https://doi.org/10.1016/j.lungcan.2004.02.016

Zobrazit plný text záznamu

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy

Autor: P Recloux, O Van Cutsem, Jean-Paul Sculier, Michel Richez, Jean-Jacques Lafitte, Vincent Ninane, Marianne Paesmans, Thierry Berghmans, Jean Klastersky, Paul Mommen

Publikováno v: Lung Cancer. 37:73-77

The purpose of this study was to determine the activity of paclitaxel as a second-line chemotherapy for non-small cell lung cancer (NSCLC). This multicentric trial included patients who had failed to a first-line chemotherapy with platinum derivative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fbcebc0eb6a532a9cd54152e4686594
https://doi.org/10.1016/s0169-5002(02)00037-5

Zobrazit plný text záznamu

A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer

Autor: Constantinos Alexopoulos, Vincent Ninane, M.C. Florin, Paul Mommen, Jacques Thiriaux, P Recloux, Anna Efremidis, J. Lecomte, Thierry Berghmans, Jean Klastersky, Marianne Paesmans, Jean-Jacques Lafitte, Jean-Paul Sculier

Publikováno v: Annals of Oncology. 13:874-882

Objective To determine, in stage IV non-small-cell lung cancer (NSCLC), if the combination of gemcitabine—a new active drug—with ifosfamide (IG) or with the cisplatin-carboplatin association (CCG) will improve survival (primary end point) in comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ab15e9d9e15443e6cad6024946c3e84
https://doi.org/10.1093/annonc/mdf154

Zobrazit plný text záznamu

Prognostic factors for patients with small cell lung carcinoma

Autor: Gérard Bureau, Paul Mommen, Vincent Ninane, Jean-Paul Sculier, Marianne Paesmans, P. Libert, Roger Sergysels, G Dabouis, Jean Klastersky, J. Lecomte, Jacques Thiriaux, O Van Cutsem

Publikováno v: Cancer. 89:523-533

BACKGROUND The purposes of this study were to identify prognostic factors for response to chemotherapy, overall survival, and long term survival of patients with small cell lung carcinoma and to construct a classification of patients on the basis of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18e369956cdda6d150b3eab072d42d95
https://doi.org/10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co

Zobrazit plný text záznamu

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer

Autor: Jacques Thiriaux, Jean-Jacques Lafitte, Paul Mommen, Jean-Paul Sculier, Anna Efremidis, J. Lecomte, Jean Klastersky, Thierry Berghmans, Marianne Paesmans, Vincent Ninane

Publikováno v: Lung Cancer. 29:67-73

The purpose of the present trial was to determine the activity of gemcitabine as a second-line chemotherapy for non small cell lung cancer (NSCLC). To be eligible, patients had to have pathologically proven NSCLC that has failed to respond to a first

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4913403c123a56219536682401ca0401
https://doi.org/10.1016/s0169-5002(00)00099-4

Zobrazit plný text záznamu

A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer

Autor: George Koumakis, Jean-Paul Sculier, Marianne Paesmans, Jacques Thiriaux, Jean Klastersky, Gérard Bureau, Constantinos Zacharias, Constantinos Alexopoulos, V. Giner, Paul Mommen, Vincent Ninane, Jean-Jacques Lafitte, M.C. Berchier, J. Lecomte

Publikováno v: European Journal of Cancer. 35:1314-1319

We retrospectively analysed the data obtained in a large randomised trial performed in 505 eligible patients with advanced non-small cell lung cancer. Its purpose had been to compare a combination of carboplatin (200 mg/m2) and cisplatin (60 mg/m2) w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::797d5d162fa361e977cebd4588dbf5c0
https://doi.org/10.1016/s0959-8049(99)00029-5

Zobrazit plný text záznamu

Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party

Autor: Anna Efremidis, Jacques Thiriaux, Jean Klastersky, Constantinos Zacharias, Paul Mommen, Jean-Jacques Lafitte, Marianne Paesmans, M.C. Berchier, Jean-Paul Sculier, Vincent Ninane, V. Giner, Constantinos Alexopoulos, Jean-Sébastien Lecomte, Gérard Bureau

Publikováno v: Journal of Clinical Oncology. 16:1388-1396

PURPOSE A phase III randomized trial in patients with advanced non-small-cell lung cancer (NSCLC) was performed to determine if the addition of ifosfamide to moderate-dose cisplatin and carboplatin improved response rate (primary end point) and survi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8d611ab80bd156538a502fa59bd0628
https://doi.org/10.1200/jco.1998.16.4.1388

Zobrazit plný text záznamu

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party

Autor: Paul Mommen, Roger Sergysels, Jean Klastersky, G Dabouis, Jacques Thiriaux, J. Michel, Marianne Paesmans, O Van Cutsem, Jean-Paul Sculier, Gérard Bureau, P. Libert

Publikováno v: European Journal of Cancer. 33:2326-2332

The aim of this study was the assessment of the predictive value for survival of an antitumoral response to three courses of chemotherapy in association with various pretreatment characteristics in patients with non-resectable non-small cell lung can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf13a6c6dd61470eed518a3c56fad724
https://doi.org/10.1016/s0959-8049(97)00325-0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání